Huang Jinzhong, Hong Wei, Yang Zhilong, Ding Jian, Ren Yi
Department of Neurology, the Third Affiliated Hospital of Soochow University, Changzhou, Jiangsu, China.
J Int Med Res. 2020 Jul;48(7):300060520922449. doi: 10.1177/0300060520922449.
To investigate the efficacy of combining the dopamine receptor agonist pramipexole with levodopa for Parkinson's disease (PD) treatment and to measure their effects on quality of life and tumor necrosis factor (TNF)-α levels in PD patients.
In total, 160 PD patients who were admitted to our hospital were equally randomized into a control treatment group (levodopa alone) and the study group (pramipexole combined with levodopa). Both groups were treated for 12 weeks.
After treatment, scores from the Unified Parkinson's Disease Rating Scales (1-3), the Hamilton Depression Scale, and the Parkinson's Disease Questionnaire (PDQ-39) were significantly decreased in both groups, whereas Mini-Mental State Examination scores were significantly increased. After treatment, the study group had significantly lower scores for all scales except the Mini-Mental State Examination, for which those who received combined treatment had significantly higher scores than the control group. The incidence of adverse reactions was significantly lower in the study group than in the control group. Furthermore, after treatment, serum TNF-α levels were significantly decreased in both groups compared with pre-treatment levels.
Pramipexole combined with levodopa relieved PD symptoms and improved the quality of life of PD patients, potentially by suppressing serum TNF-α levels.
研究多巴胺受体激动剂普拉克索与左旋多巴联合用于治疗帕金森病（PD）的疗效，并测定其对PD患者生活质量和肿瘤坏死因子（TNF）-α水平的影响。
总共160例入住我院的PD患者被随机均分为对照治疗组（单用左旋多巴）和研究组（普拉克索联合左旋多巴）。两组均治疗12周。
治疗后，两组的统一帕金森病评定量表（1-3）、汉密尔顿抑郁量表及帕金森病问卷（PDQ-39）评分均显著降低，而简易精神状态检查表评分显著升高。治疗后，除简易精神状态检查表外，研究组所有量表的评分均显著低于对照组，接受联合治疗者在该检查表上的评分显著高于对照组。研究组不良反应的发生率显著低于对照组。此外，治疗后两组血清TNF-α水平均较治疗前显著降低。
普拉克索联合左旋多巴可缓解PD症状，提高PD患者的生活质量，其机制可能是通过抑制血清TNF-α水平实现的。
